Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-07-12 am EDT			5-day change	1st Jan Change
980.3 ^DKK	+1.34%		+0.65%	+40.42%

Jul. 12	Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	RE
Jul. 12	Ozempic linked with lower dementia risk, nicotine use, British study finds	RE

NOVO NORDISK : JP Morgan keeps its Buy rating

January 03, 2023 at 05:28 am EST

In a research note published by Richard Vosser, JP Morgan advises its customers to buy the stock. The target price has been raised from DKK 925 to DKK 1100.

Latest news about Novo Nordisk A/S

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	Jul. 12	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	Jul. 12	RE
European Equities Close Higher in Friday Trading; Unilever to Cut 3,200 European Jobs	Jul. 12	MT
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	Jul. 12	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	Jul. 12	RE
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says	Jul. 12	MT
NOVO NORDISK : Buy rating from Deutsche Bank	Jul. 12	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	Jul. 11	DJ
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	Jul. 11	MT
Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan...	Jul. 11
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	Jul. 11	MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia	Jul. 11	MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia	Jul. 11	MT
Pfizer moves forward with once-daily weight loss drug	Jul. 11	RE
Novo Nordisk Gets Complete Response Letter from US FDA for Insulin Icodec Application	Jul. 11	MT
NOVO NORDISK : Goldman Sachs reiterates its Buy rating	Jul. 11	ZD
NOVO NORDISK : JP Morgan reaffirms its Buy rating	Jul. 11	ZD
Gerresheimer core profit meets forecast on weight-loss drug deals pipeline	Jul. 11	RE
Novo Nordisk: FDA applications for icodec	Jul. 11	CF
Novo Nordisk Receives Additional Information Request from US FDA for Insulin Icodec	Jul. 11	MT
Novo Nordisk Signs MoU with Indonesia's Bio Farma for Insulin Packaging	Jul. 11	MT
US FDA declines to approve Novo Nordisk's weekly insulin	Jul. 10	RE
Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec	Jul. 10	CI
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	Jul. 10	RE
SANDERS SAYS HE IS CURRENTLY FOCUSED ON NOVO NORDISK BUT WILL 'C…	Jul. 10	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 12:36 pm EDT

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 12:09 pm EDT

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am EST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

980.3 DKK

Average target price

956.5 DKK

Spread / Average Target

-2.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+40.42%	636B
ELI LILLY AND COMPANY	+62.66%	854B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B
PFIZER, INC.	+0.45%	164B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : JP Morgan keeps its Buy rating

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals